Erez Chimovits
CIK: 0001706399
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Aug 7, 2026BRVE
Braveheart Bio, Inc.
Purchase(P)Indirect1.7M shares at avg. $18.00$30.0M - Aug 7, 2026BRVE
Braveheart Bio, Inc.
Purchase(P)Indirect273.3K shares at avg. $18.00$4.9M - Aug 7, 2026BRVE
Braveheart Bio, Inc.
Conversion(C)Indirect9.1M shares- - Aug 5, 2026BRVE
Braveheart Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
30K shares- - Jun 9, 2026UPB
Upstream Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
17.1K shares- - Jun 10, 2025UPB
Upstream Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
17.1K shares- - Oct 15, 2024UPB
Upstream Bio, Inc.
Conversion(C)Indirect2.9M shares- - Oct 15, 2024UPB
Upstream Bio, Inc.
Conversion(C)Indirect722K shares- - Oct 15, 2024UPB
Upstream Bio, Inc.
Purchase(P)Indirect165K shares at avg. $17.00$2.8M - Oct 15, 2024UPB
Upstream Bio, Inc.
Purchase(P)Indirect660K shares at avg. $17.00$11.2M - Oct 10, 2024UPB
Upstream Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
17.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 7, 2026 |  BRVE Braveheart Bio, Inc. | Purchase(P) | 1,666,667 | $18.00 | $30,000,006 | Indirect |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Purchase(P) | 273,333 | $18.00 | $4,919,994 | Indirect |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Conversion(C) | 9,132,420 | - | $0 | Indirect |
| Aug 5, 2026 | BRVE Braveheart Bio, Inc. | Award(A) Stock Option (Right to Buy) | 30,000 | - | - | Direct |
| Jun 9, 2026 |  UPB Upstream Bio, Inc. | Award(A) Stock Option (Right to Buy) | 17,096 | - | - | Direct |
| Jun 10, 2025 | UPB Upstream Bio, Inc. | Award(A) Stock Option (Right to Buy) | 17,096 | - | - | Direct |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | Conversion(C) | 2,887,833 | - | $0 | Indirect |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | Conversion(C) | 721,956 | - | $0 | Indirect |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | Purchase(P) | 165,000 | $17.00 | $2,805,000 | Indirect |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | Purchase(P) | 660,000 | $17.00 | $11,220,000 | Indirect |
| Oct 10, 2024 | UPB Upstream Bio, Inc. | Award(A) Stock Option (Right to Buy) | 17,096 | - | - | Direct |
1-11 of 11 transactions
About Chimovits Erez
Chimovits Erez (SEC CIK 0001706399) files insider reports with the SEC as Director of ADARx Pharmaceuticals, Inc. (ADRX), Director of Braveheart Bio, Inc. (BRVE) and Director of Upstream Bio, Inc. (UPB).
Signal8 holds 9 ownership filings by Chimovits Erez (3 Form 3, 6 Form 4), filed between Oct 10, 2024 and Sep 24, 2026. Those filings report 11 transactions, from Oct 10, 2024 to Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Chimovits Erez's filings is in SAN DIEGO, CA.
Recent filings by Chimovits Erez
- Aug 7, 2026: Open-market purchases of BRVE shares (2 lines, Form 4, code P).
- Aug 7, 2026: Conversion of BRVE shares (Form 4, code C).
- Aug 5, 2026: Grant or award of BRVE derivative securities (Form 4, code A).
- Jun 9, 2026: Grant or award of UPB derivative securities (Form 4, code A).
- Jun 10, 2025: Grant or award of UPB derivative securities (Form 4, code A).
Other insiders filing for ADARx Pharmaceuticals, Inc. (ADRX)
- SR ONE CAPITAL MANAGEMENT, LLC, 10% Owner
- George Simeon, Director
- LAV Biosciences Fund V, L.P., 10% Owner
- Zhu Rui (NMN), Chief Technology Officer
- MacLeod Alan Robert, Chief Scientific Officer
- Fisk Ryan, CFO and CBO